Market Place
Sourcing Support
Gilead to pay $202 M in US settlement over HIV drug kickbacks
30 Apr 2025 //
REUTERS
Gilead supports long-acting PrEP launch despite uncertainties
25 Apr 2025 //
FIERCE PHARMA
Gilead posts profit, HIV prevention drug on track for mid-June
24 Apr 2025 //
REUTERS
Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025 //
BUSINESSWIRE
Gilead mounts campaign to close UK’s ‘HIV gender gap’
23 Apr 2025 //
FIERCE PHARMA
Gilead Backs HIV Prevention Summit in Atlanta
22 Apr 2025 //
ACCESSWIRE
Gilead says Trodelvy-Keytruda combo effective for breast cancer
22 Apr 2025 //
REUTERS
Ipsen touts early launch results for liver disease drug Iqirvo
17 Apr 2025 //
FIERCE PHARMA
Nurix`s GS-6791/NX-0479 IRAK4 Degrader IND Cleared by FDA
17 Apr 2025 //
GLOBENEWSWIRE
IDEAYA Biosciences Expands IDE397 and Trodelvy Combo in MTAP-Dele
10 Apr 2025 //
PR NEWSWIRE
Gilead Sciences to Release Q1 2025 Financial Results on April 24
10 Apr 2025 //
BUSINESSWIRE
Centrifuge Sessions Drive Cancer Research Innovation
03 Apr 2025 //
ACCESSWIRE
Gilead Sciences in Top Five on JUST List for Biopharma Companies
18 Mar 2025 //
ACCESSWIRE
Gilead Sciences - Women`s History Month Celebrated With Its Team
14 Mar 2025 //
ACCESSWIRE
Gilead Reveals New HIV Treatment and Cure Data at CROI 2025
12 Mar 2025 //
BUSINESSWIRE
Gilead sets aside $200M for settlement over HIV drug
05 Mar 2025 //
FIERCE PHARMA
MEDSIR, Debiopharm Dose First Patient In WIN-B Breast Cancer Trial
25 Feb 2025 //
BUSINESSWIRE
EMA Validates Gilead’s MAA For Lenacapavir In HIV Prevention
24 Feb 2025 //
BUSINESSWIRE
Gilead`s Seladelpar Gets EU Conditional Nod For Biliary Cholangitis
20 Feb 2025 //
BUSINESSWIRE
Gilead Showcases Autoimmune Impact In The Centrifuge Sessions
19 Feb 2025 //
ACCESSWIRE
Gilead Sciences to Present at Upcoming Investor Conferences
19 Feb 2025 //
BUSINESSWIRE
FDA Grants Review To Gilead’s Lenacapavir For HIV Prevention
18 Feb 2025 //
BUSINESSWIRE
Nurix Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
14 Feb 2025 //
GLOBENEWSWIRE
Ideaya & Gilead To Study Trodelvy + IDE397 Combo In MTAP-Deleted NSCLC
13 Feb 2025 //
PR NEWSWIRE
Gilead provides upbeat 2025 forecast, shares rise 4%
12 Feb 2025 //
REUTERS
GSK questions Gilead`s potential dominance of the PrEP market
07 Feb 2025 //
FIERCE PHARMA
Energize Supports Global Healthcare Firms with Multi-buyer PPA
06 Feb 2025 //
BUSINESSWIRE
Gilead to Release Q4 & Full Year 2024 Financial Results Feb 11
28 Jan 2025 //
BUSINESSWIRE
Gilead, US government resolve long-running HIV patent dispute
17 Jan 2025 //
PRESS RELEASE
Gilead, LEO Pharma to programs for inflammatory diseases
13 Jan 2025 //
REUTERS
Galapagos splits in 2, laying off 40% of staff
08 Jan 2025 //
FIERCE BIOTECH
Gilead Sciences to Present at Upcoming Investor Conference
20 Dec 2024 //
BUSINESSWIRE
Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials
20 Dec 2024 //
FIERCE BIOTECH
Gilead & Terray Announce Multi-Target Research Collaboration
17 Dec 2024 //
BUSINESSWIRE
AI-powered Terray is teaming up with Gilead in a fresh R&D pact
17 Dec 2024 //
FIERCE BIOTECH
Gilead`s Seladelpar Receives CHMP Nod For Biliary Cholangitis
13 Dec 2024 //
BUSINESSWIRE
Gilead appoints Sanofi official Dietmar as next CMO
13 Dec 2024 //
REUTERS
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
Gilead spotlights lenacapivir in plan to hold on to HIV crown
11 Dec 2024 //
FIERCE PHARMA
Kite’s Tecartus CAR T Therapy Shows Durable Efficacy at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Shows Durable Response in Relapsed Lymphomas
09 Dec 2024 //
BUSINESSWIRE
Kite`s Yescarta® Highlights Curative Potential in Relapsed Lymphoma
08 Dec 2024 //
BUSINESSWIRE
Gilead taps Tubulis for solid tumor ADC development worth up to $465M
04 Dec 2024 //
PRESS RELEASE
Gilead Announces NEJM Publication of PURPOSE 2 Results
27 Nov 2024 //
BUSINESSWIRE
Designing Inclusive Trials in an Effort To Upend the HIV Epidemic
26 Nov 2024 //
ACCESSWIRE
Gilead buys HIV vaccine from biotech following clinical collab
26 Nov 2024 //
FIERCE BIOTECH
Gilead supports ‘sanctuary’ for Black breast cancer patients
20 Nov 2024 //
FIERCE PHARMA
Ideaya hires Gilead leader to head up commercialization push
19 Nov 2024 //
FIERCE PHARMA
Gilead cuts 100+ positions at California HQ
18 Nov 2024 //
FIERCE PHARMA
Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis
15 Nov 2024 //
BUSINESSWIRE
Gilead to lay off 72 staffers, shutter Seattle R&D office
14 Nov 2024 //
FIERCE BIOTECH
Gilead Presents PURPOSE 2 Data on Lenacapavir for HIV Prevention
13 Nov 2024 //
BUSINESSWIRE
Gilead Prices $3.5 Billion of Senior Unsecured Notes
13 Nov 2024 //
BUSINESSWIRE
Gilead Presents Research on Broad HIV Treatment Portfolio
12 Nov 2024 //
BUSINESSWIRE
Gilead`s CAR-T sales stagnate as Trodelvy takes another write-off
11 Nov 2024 //
FIERCE PHARMA
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
11 Nov 2024 //
FIERCE PHARMA
Gilead Sciences to Present at Upcoming Investor Engagements
08 Nov 2024 //
BUSINESSWIRE
Gilead Presents Data & Extends HIV Leadership at HIV Glasgow
07 Nov 2024 //
BUSINESSWIRE
Gilead Q3 results beat Wall Street estimates, raises outlook
07 Nov 2024 //
REUTERS
Gilead Sciences Announces Q3 2024 Financial Results
06 Nov 2024 //
BUSINESSWIRE
